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Background: MicroRNAs (miRNAs) are small non-coding genes which become dysregulated in cancer
and may predict survival. The role of miRNAs in outcomes in cholangiocarcinoma (CC) has not been
reported.
Methods: RNA was extracted from 32 resected CCs along with adjacent uninvolved bile duct epithelium.
A total of 43 miRNAs were quantified using NanoString™. Clinicopathologic characteristics and out-
comes were captured and compared. Overall survival curves were created using the Kaplan–Meier
method; factors, including miRNA expression, were compared by log-rank, chi-squared or Cox regression
analyses.
Results: Absolute expression of each miRNA was compared with overall survival after excluding perio-
perative deaths (n = 3). One upregulated (miR-151-3p; P = 0.003) and one downregulated (miR-126; P =
0.023) miRNA in resected CC relative to adjacent normal bile duct epithelium correlated with survival on
univariate analysis. Clinical factors and these miRNAs were compared. Dysregulated miR-151-3p and
miR-126, respectively, were the only factors that correlated with improved overall survival [41.5 months
vs. 12.3 months (P = 0.002) and 21.9 months vs. 15.1 months (P = 0.02), respectively]. In eight patients,
both miRNAs were dysregulated. In the remainder, only one or neither showed dysregulation. Concomi-
tant dysregulation correlated with the best overall survival (58.7 months vs. 15.1 months; P < 0.000;
n = 8); clinicopathologic factors in these groups were otherwise similar.
Conclusions: In resected CC, the concomitant dysregulation of both miR-151-3p and miR-126 was the
factor related to the greatest improvement in overall survival. Further analysis of the targets of these
miRNAs may yield potential therapeutic targets or prognostic biomarkers.
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Introduction
Cholangiocarcinoma (CC) is a primary hepatic malignancy origi-
nating from bile duct epithelium. It is the second most common
primary hepatic neoplasia and, although rare, accounts for
approximately 3% of all gastrointestinal malignancies.1 Over 3500
cases will be diagnosed in the USA this year alone. Further, the
worldwide incidence of CC and associated mortality rates are
increasing.2 Hepatobiliary cancer accounts for 13% of the
7.6 million cancer-related deaths worldwide each year; of these,
CC accounts for 10–20%.3 Because of its poor prognosis,
incidence and prevalence are essentially the same.
Risk factors for CC include chronic inflammation, primary
sclerosing cholangitis (PSC), infestation with liver flukes, congeni-
tal disorders (e.g. choledochal cysts), hepatolithiasis, viral hepati-
tis, and lifestyle choices (i.e. ethanol use, obesity, smoking). Most
patients with CC have no identifiable risk factors. Effective screen-
ing tools for CC are lacking and the disease remains difficult to
diagnose. In patients identified as high risk (i.e. patients with
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chronic viral hepatitis and PSC), there are no reliable screening
methods. Even histopathology can be deficient in making a diag-
nosis after resection or biopsy.
The only definitive curative therapy is surgical resection in
those patients without distant or locally advanced disease. Despite
aggressive resection, overall survival is poor and 5-year survival
rates range from 20% to 35%.4–9 In patients with advanced disease,
survival remains limited.10 In patients with advanced disease, the
standard of care includes gemcitabine-based chemotherapy or
enrolment in a clinical trial. Growing understanding of the
molecular and cellular aetiology of this disease is enabling the
development of novel targeted therapies. However, little is known
about the pathogenesis of CC.
MicroRNAs (miRNAs) are small (20–22 nucleotides), non-
coding RNA fragments that have critical functions in various bio-
logical processes. To date, over 1000 miRNAs have been reported
and shown to play a role in cell proliferation, apoptosis and dif-
ferentiation. They are linked to oncogenesis through their func-
tion as oncogenes or tumour suppressors.11
The present authors have noted anecdotally that a subset of
patients undergoing resection for CC appear to do better than
others for unclear reasons. Therefore, this group hypothesized
that key miRNAs can be utilized to characterize a subset of
patients with resectable CC in whom overall survival will be
improved and that these miRNAs will thus be prognostic. Further,
these miRNAs modulate protein expression involved in tumour
growth and may serve as potential targets for future therapies.
Materials and methods
Institutional review board approval was obtained for the retrieval
of data from the archival files of the Department of Pathology at
this institution. A total of 135 patients presenting with CC
between 1993 and 2007 were subsequently identified. Of these, 90
underwent surgical exploration. Of the 69 who underwent resec-
tion with curative intent, tissue samples for 32 patients were of
adequate volume for RNA extraction. Three 2-mm cores of
tumour and matched adjacent benign bile duct epithelium were
punched from paraffin blocks. Deparaffinization using 100%
xylene at 50 °C for 3 min was followed by RNA extraction using
the RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion®, Life
Technologies, Corp., Grand Island, NY, USA) according to the
manufacturer’s guidelines. Calculation of the miRNA using the
NanoString nCounter® Analysis System (NanoString Technolo-
gies, Inc., Seattle, WA, USA) was performed according to the
manufacturer’s protocol. This method is described elsewhere.12
Selected miRNAs were validated by reverse transcription poly-
merase chain reaction (RT-PCR) using standard protocols and are
reported elsewhere.13
Statistical analysis
NanoString nCounter® provides a quantitative assessment of
miRNA expression. Dysregulated miRNA expression was defined
as aberrant expression compared with that in normal adjacent bile
duct epithelium. The expression of each dysregulated miRNA was
dichotomized as ‘high’ or ‘low’ relative to the mean tumour
expression of each miRNA. These data were then correlated with
clinical outcomes.
The Kaplan–Meier method was used to construct overall and
progression-free survival curves. Time-to-event variables were
calculated from the time of resection. Log-rank analysis was used
to compare groups. Perioperative deaths were considered as
deaths that occurred within 60 days of resection or during the
index admission and were excluded from all survival and recur-
rence analyses. Progression was determined by the date when
either intra- or extrahepatic progression of disease was noted
radiographically. Categorical variables were analysed using Pear-
son’s chi-square or Fisher’s exact test as appropriate. Student’s
t-test was used to analyse continuous variables. All tests were
examined at a two-tailed significance level of 0.05. Cox regression
multivariate analysis was used to compare factors associated with
survival. All factors were included and analysed in a forward step-
wise fashion. Logistic regression multivariate analysis was used to
compare associations with the differential expression of miRNAs
of interest. All factors were included and analysed in a forward
stepwise fashion; however, because data for carbohydrate antigen
19-9 (CA 19-9) were missing for 12 patients, this factor was
excluded from the final analysis.
Results
A total of 32 patients with CC resected with curative intent for
whom adequate pathologic specimens were available for miRNA
analysis were identified. Patients were, on average, in their seventh
decade (Table 1). The majority were female and had extrahepatic
tumours, eight of which were hilar. Almost half of the patients had
elevated CA 19-9 and/or obstructive jaundice preoperatively
(Table 1).
The majority of the patients (n = 20, 63%) were classified as
having stage I or II disease (American Joint Commission on
Cancer, Cancer Staging Manual, 7th edn).14 Thus, only about one
Table 1 Demographic data for patients undergoing resection for
cholangiocarcinoma (n = 32)
Characteristics Data
Age, years, median (range) 66 (47–85)
Gender, male, n 12
Tumour location, n Intrahepatic, 11
Hilar, 8
Distal, 13
Elevated CA 19-9, n 15
CA 19-9, mL, median (range) 51.3 (<15–9000)
Elevated bilirubin, n 13
Adjuvant chemotherapy, n 10/29
CA 19-9, carbohydrate antigen 19-9.
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third of patients underwent adjuvant chemotherapy (Table 1).
Two thirds of the tumours were moderately differentiated and
showed perineural invasion (PNI) (Table 2). Only one third of
patients demonstrated lymphovascular invasion (LVI) or nodal
disease. The majority of the patients had negative resection
margins (Table 2).
Seven patients (22%) had perioperative complications, includ-
ing multi-organ system failure (n = 1), sepsis (n = 2), anastomotic
leak or bleeding (n = 3) and bronchobiliary fistula (n = 1)
(Table 2). Three patients (9%) died perioperatively, one of whom
was the patient with multi-organ failure. The other two died at
>30 days after discharge of unknown causes. Median overall sur-
vival was 17.8 months. Seven patients were lost from follow-up.
Of the remaining 22 patients, 16 (73%) patients experienced
disease recurrence at a median of 17.0 months (range: 6.6–
89.0 months). In the majority of patients (n = 15, 68%), recur-
rence was either intrahepatic or in the porta hepatis. Only one
patient, who has been followed for 89 months, survived to the
completion of this study.
Expression of 43 miRNAs in the study specimens was found to
be dysregulated in comparison with that in adjacent normal bile
duct epithelium. Of these, 17 were upregulated and 26 were down-
regulated. When these data were correlated with outcomes, dys-
regulations of two miRNAs were found to be associated with
improvements in overall survival from the time of resection. High
expression of miR-151-3p was associated with improved median
survival of 41.5 months compared with 12.3 months (P = 0.004).
Low expression of miR-126 was associated with improved median
survival of 21.9 months compared with 15.1 months (P = 0.033).
A stronger association with overall survival emerged when both
miRNAs were dysregulated (58.7 months vs. 15.1 months; P <
0.000) (Fig. 1). These miRNAs did not predict recurrence or time
to recurrence (P = 0.71).
When other clinicopathologic factors were analysed individu-
ally for association with overall survival, the only factors found to
be prognostic were dysregulations of miR-126 and miR-151-3p
(Table 3). When all clinicopathologic factors were analysed in a
multivariate stepwise fashion, only differential expression of both
miRNAs correlated with an improvement in overall survival (P =
0.04, hazard ratio 0.201, 95% confidence interval 0.043–0.928).
The absence of LVI correlated with the differential expression of
both miRNAs when clinicopathologic factors were compared
(Table 4). When all factors were analysed in a forward stepwise
fashion, no factors appeared to have an independent association;
Table 2 Perioperative and pathologic factors in patients undergoing
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Figure 1 High expression of miR-151-3p and low expression of miR-
126 predict overall survival after resection for cholangiocarcinoma
(n = 9)





High miR-151-3p expression 0.004 0.944
Low miR-126 expression 0.033 0.434
Dysregulation in both miRNAs 0.000 0.040
Tumour size 0.674 0.613
Nodal metastasis 0.122 0.359
Margins 0.368 0.217
Tumour location 0.311 0.791
Grade 0.324 0.213
Fibrosis 0.767 0.229
Elevated bilirubin 0.546 0.690
Elevated CA 19-9 0.875 0.909
Perineural invasion 0.771 0.648
Lymphovascular invasion 0.548 0.132
Adjuvant chemotherapy 1.000 0.756
CA 19-9, carbohydrate antigen 19-9.
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however, the trend towards an association with the absence of LVI
remained.
Discussion
It has become clear that miRNAs are important in normal physi-
ologic processes and even more important in cancer. Often
intronic, these non-coding fragments of RNA are capable of
affecting the post-transcription regulation of up to hundreds of
genes. They are highly conserved among species and their small
size makes them remarkably resistant to degradation. Thus, it is
possible to utilize small tissue samples from tumour types that are
inherently difficult to study. The present study utilized the latest
NanoString™ technology to identify a set of dysregulated miRNAs
and, for the first time, identified two miRNAs, miR-151-3p and
miR-126, with prognostic potential. These two miRNAs, particu-
larly when concordantly dysregulated, are the only factors prog-
nostic of survival in this sample of patients.
In this study, all available paraffin-embedded blocks containing
tissue from patients who had undergone resection with curative
intent and were recorded in the study institution’s database were
retrieved. Given the scarcity of availability and the inherent diffi-
culty of extracting RNA from paraffin-embedded tissue, only 32
samples were found to include adequate RNA for analysis. None-
theless, a set of 43 miRNAs that showed significant dysregulation
in tumour tissue relative to adjacent normal ductal epithelium was
identified. Of these, dysregulations of miR-151-3p and miR-126
were prognostic of overall survival, although they did not corre-
late with other typical clinicopathologic characteristics. The asso-
ciation with overall survival was particularly striking when both
miRNAs were dysregulated and appeared to be an independent
predictor of outcome. This novel expression profile and its rela-
tion to survival may aid in further identifying key miRNAs in the
development of CC and elucidate the heterogeneous population
that develops CC.
Similarly, other investigators have distinguished potential clini-
cally important miRNAs in CC. One investigation demonstrated a
cluster of 38 miRNAs distinguishing CC from normal tissue and
demonstrated that the exogenous expression of miR-320 or miR-
204 could negatively regulate Mcl-1 or Bcl-2 expression and facili-
tate chemotherapeutic drug-triggered apoptosis.15 Mcl-1 protein
expression also appeared to be regulated by miR-29 in malignant
cholangiocytes.16 Additionally, in cholangiocytes, miR-21 has been
shown to be overexpressed in CC and may be oncogenic by inhib-
iting TIMP3, a potential tumour suppressor gene in the biliary
tree,17 or modulating gemcitabine-induced apoptosis.18 One group
investigated the expression of miRNAs in hepatocellular carcinoma
(HCC) and CC related to clinical factors.19 They found several
miRNAs to be associated with tumour stage, prognosis and cirrho-
sis in HCC, but did not find the same associations in CC.19 Finally,
miR-9 identified in bile may be a diagnostic marker of CC.20
Certainly, these miRNAs may play a protective role in the devel-
opment of CC as this subset of patients does significantly better
than others undergoing resection. The present authors are
unaware of any studies investigating this potential. By contrast,
one study of the effects of miR-151 in HCC has shown that miR-
151-5p significantly increases migration and invasion by directly
targeting a metastasis suppressor.21 This study did not find the
same effect with miR-151-3p.21
Several authors have demonstrated the association between
miR-126 and carcinogenesis.22–26 Many of these studies have
shown that a downregulation of miR-126 induced carcinogenesis
and that miR-126 is a tumour suppressor itself.22–26 These findings
contrast with those of the present study. Low expression of miR-
126 in the tumour samples in the present series correlated with
improved median survival and may be protective in terms of
overall survival. In concordance with the present findings, one
investigation demonstrated that expression of miR-126 was lower
in gastric cancer than in normal surrounding tissue, but this was
not correlated with outcomes.27 Additionally, miR-126 has been
shown to play a role in inflammation and, more specifically,
angiogenesis during inflammation. This role may also influence
angiogenesis in tumour cells.28 Just as there appears to be variation
in the level of expression of miR-126 and its role in oncogenesis,
there is also variation in the proposed downstream targets. It is
this heterogeneity in the expression and action of miRNAs that
warrants further investigation into their utility as potential
cancer-specific therapeutic targets.
The correlation between an absence of LVI and the presence of
miRNAs may be of additional prognostic importance. Many
authors have shown that in tumours of the pancreatic and biliary
tree, the presence of LVI portends a poor prognosis.29,30 Although
LVI was not prognostic in the present cohort of patients, the
absence of LVI was found to correlate with the miRNAs associated
with improved prognosis.
Table 4 Clinicopathologic factors correlated with concordant dys-





Age <70 years 0.681 0.412
Gender 1.000 0.769
Tumour size 0.116 0.441
Nodal metastasis 1.000 0.891
Margins 0.704 0.516
Tumour location 0.129 0.288
Grade 0.359 0.365
Fibrosis 1.000 0.822
Elevated bilirubin 0.856 0.916
Elevated CA 19-9 0.608 a
Perineural invasion 0.938 0.412
Lymphovascular invasion absent 0.050 0.053
aElevation of CA 19-9 was excluded from the analysis because these
data were missing for 12 patients.
CA 19-9, carbohydrate antigen 19-9.
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Given the retrospective nature of the present study and its use
of archival tissue, its findings should be interpreted with caution,
although they do offer a platform for future research. Although
the current findings of the impact of dysregulation in these two
miRNAs on overall survival are striking, the present sample size
and the fact that selection was dependent on the harvesting of
adequate RNA introduce the potential for unavoidable bias.
Therefore, the present authors plan to validate these findings pro-
spectively. Once validated, these miRNAs may be useful in strati-
fying patients for clinical trials and in determining which patients
might benefit from adjuvant therapies. Further, the present
authors are investigating target proteins of these miRNAs in
immunohistochemistry to identify potential prognostic biomark-




1. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. (2009)
Evidence-based approach to cholangiocarcinoma: a systematic review of
the current literature. J Am Coll Surg 208:134–147.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. (2005) Cho-
langiocarcinoma. Lancet 366:1303–1314.
3. Shaib YH, Davila JA, McGlynn K, El-Seraq HB. (2004) Rising incidence of
intrahepatic cholangiocarcinoma in the United States: a true increase?
J Hepatol 40:472–477.
4. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. (2003)
Hepatectomy with portal vein resection for hilar cholangiocarcinoma:
audit of 52 consecutive cases. Ann Surg 238:720–727.
5. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N et al.
(1999) Extended resections for hilar cholangiocarcinoma. Ann Surg
230:808–818.
6. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. (1999)
Improved surgical results for hilar cholangiocarcinoma with procedures
including major hepatic resection. Ann Surg 230:663–671.
7. Baton O, Azoulay D, Adam DV, Castaing D. (2007) Major hepatectomy for
hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm
outcomes. J Am Coll Surg 204:250–260.
8. Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ
et al. (2002) Improved survival in resected biliary malignancies. Surgery
132:555–563.
9. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J et al.
(2005) Prognostic factors of surgical resection in middle and distal bile
duct cancer: an analysis of 55 patients concerning the significance of
ductal and radial margins. Surgery 137:396–402.
10. Yachimski P, Pratt DS. (2008) Cholangiocarcinoma: natural history,
treatment, and strategies for surveillance in high-risk patients. J Clin
Gastroenterol 42:178–190.
11. Croce CM. (2008) Oncogenes and cancer. N Engl J Med 358:502–511.
12. Fortina P, Surrey S. (2008) Digital mRNA profiling. Nat Biotechnol 26:293–
294.
13. Collins A, Wojcik S, Frankel W, Alder H, Yu L, Croce CM et al. (2011) A
differential microRNA profile distinguishes cholangiocarcinoma from pan-
creatic adenocarcinoma. J Am Coll Surg 213 (Suppl.): 133 [Abstract].
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (2010)
AJCC Cancer Staging Manual, 7th edn. New York, Springer.
15. Chen L, Yan H-X, Yang W, Hu L, Yu LX, Liu Q et al. (2009) The role of
microRNA expression pattern in human intrahepatic cholangiocarcinoma.
J Hepatol 50:358–369.
16. Mott JL, Kobayashi S, Bronk SF, Gores GJ. (2007) Mir-29 regulates Mcl-1
protein expression and apoptosis. Oncogene 26:6133–6140.
17. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y et al. (2009)
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regu-
lates programmed cell death and tissue inhibitor of metalloproteinase.
Gastroenterology 49:1595–1601.
18. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT et al.
(2006) Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology
130:2113–2129.
19. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A,
Polymeneas G, Voros D. (2011) Expression of microRNAs, miR-21, miR-
31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and
miR-223 in patients with hepatocellular carcinoma or intrahepatic cho-
langiocarcinoma and its prognostic significance. Mol Carcinog. doi:
10.1002/mc.21864 [Epub ahead of print].
20. Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahi-
gashi Y et al. (2011) Real-time PCR-based analysis of the human bile
microRNAome identifies miR-9 as a potential diagnostic biomarker for
biliary tract cancer. PLoS ONE 6:e23584.
21. Luedde T. (2010) MicroRNA-151 and its hosting gene FAK (focal adhe-
sion kinase) regulate tumour cell migration and spreading of hepatocel-
lular carcinoma. Hepatology 52:1164–1166.
22. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA et al.
(2008) MicroRNA-126 inhibits invasion in non-small cell lung carcinoma
cell lines. Biochem Biophys Res Commun 373:607–612.
23. Musiyenko A, Bitko V, Barik S. (2008) Ectopic expression of miR-126*, an
intronic product of the vascular endothelial EGF-like 7 gene, regulates
protein translation and invasiveness of prostate cancer LNCaP cells.
J Mol Med (Berl) 86:313–322.
24. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. (2008) The
non-coding RNA, miR-126, suppresses the growth of neoplastic cells by
targeting phosphatidylinositol 3-kinase signalling and is frequently lost in
colon cancers. Genes Chromosomes Cancer 47:939–946.
25. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. (2009)
Epigenetic therapy upregulates the tumour suppressor microRNA-126
and its host gene EGFL7 in human cancer cells. Biochem Biophys Res
Commun 379:726–731.
26. Feng R, Chen X, Yu Y, Su L, Yu B, Li J et al. (2010) miR-126 functions as
a tumour suppressor in human gastric cancer. Cancer Lett 298:50–63.
27. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. (2011)
MicroRNA-126 inhibits SOX2 expression and contributes to gastric car-
cinogenesis. PLoS ONE 6:e16617.
28. Meister J, Schmidt MHH. (2010) miR-126 and miR-126*: new players in
cancer. Sci World J 10:2090–2100.
29. Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M.
(2010) Predictors of survival in periampullary cancers following pancre-
aticoduodenectomy. Ann Surg Oncol 17:991–997.
30. Patel SH, Kooby DA, Staley CA III, Sarmiento JM, Maithel SK. (2011) The
prognostic importance of lymphovascular invasion in cholangiocarci-
noma above the cystic duct: a new selection criterion for adjuvant
therapy? HPB 13:605–611.
264 HPB
HPB 2013, 15, 260–264 © 2012 International Hepato-Pancreato-Biliary Association
